By: Dulan Lokuwithana
After GSK ( GSK ) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics ( TRVI ), which is advancing a rival candidate, traded higher to reach an all-time high.
Dulan Lokuwithana is an Editor for Breaking News at NewsBreak. He specializes in the intersection of finance and healthcare, covering topics such as pharmaceutical manufacturing, regulation, and advancements in gene therapy, immunology, and oncology. Dulan's insights and analyses are featured in prominent outlets like NewsBreak and Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)


Not enough data
Dulan Lokuwithana's articles predominantly focus on the healthcare and pharmaceutical industry, with an emphasis on investment analysis and press releases. To effectively pitch to Dulan, provide insights into the financial implications of developments within biotechnology, drug development, or pharmaceutical companies. This could include potential market impacts of new product launches, M&A activities, regulatory approvals or clinical trial results.
Given the high percentage of coverage attributes related to investment analysis and private sector announcements in his work, Dulan may be interested in pitches from professionals who can offer financial perspectives on company developments or those who have access to exclusive data supporting market trends within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .